As of March 31, 2026, Allergan employs 10,043 people. The company operates across broad therapeutic segments with established commercial operations in key markets. Allergan's diversified portfolio spans both specialty and generic pharmaceutical offerings.
Cyborg Score Rationale
Allergan demonstrates stability as a diversified pharmaceutical manufacturer with established therapeutic areas and significant scale. However, recent search results show limited concrete 2025-2026 financial data, and the pharmaceutical sector faces ongoing pricing pressures and competitive dynamics.
Top Insights
Diversified therapeutic portfolio reduces dependency on any single product or market segment
Global presence across dermatology, CNS, ophthalmology, and specialty care offers multiple growth vectors
Employee base of ~10,000 reflects mid-sized independent pharmaceutical operations
Generic medicine focus provides stable cash flow but faces ongoing generic pricing pressure
Named Competitors
Botox — Leading aesthetic injection treatment
Generic Pharmaceuticals Portfolio — Global generic and specialty pharma